The drug is the first approved to combine albuterol (a beta-2 adrenergic agonist) and budesonide (a corticosteroid).

AIRSUPRA is a combination of albuterol, a beta 2 -adrenergic agonist and budesonide, a corticosteroid, indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the ...

The drug-device combination product is available in 160mcg/4.5mcg and 80mcg/4.5mcg dosage strengths.

The U.S. Food and Drug Administration have approved GlaxoSmithKline's Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive pulmonary disease.

The drug-device combination product will be available in 160mcg/4.5mcg and 80mcg/4.5mcg dosage strengths.

The company is evaluating CST-103 and CST-2032, beta-2 adrenoceptor agonists, in combination with CST-107, a beta blocker, in multiple Phase 1 and 2 clinical studies.

On April 17, the Pulmonary-Allergy Drugs Advisory Committee to the FDA voted 9 to 4 to recommend approval of FF/VI 100/25 μg as a once-daily inhaled treatment for reduction of COPD exacerbations ...

Long-acting muscarinic antagonists (LAMAs), such as umeclidinium, especially in combination with long-acting beta-2-adrenergic agonists (LABAs), such as vilanterol, have been associated with an ...